Effectiveness of mesotherapy in post-covid pain syndrome: retrospective cohort study of 96 patients

dc.contributor.authorTopal, İlknur
dc.contributor.authorYılmaz, Onur
dc.date.accessioned2025-03-14T08:20:44Z
dc.date.available2025-03-14T08:20:44Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Fizik Tedavi ve Rehabilitasyon Ana Bilim Dalı
dc.description.abstractPurpose: Musculoskeletal pain may occur after becoming infected with SARS-Cov2. This study was designed to evaluate the efficacy of mesotherapy in treating chronic pain following COVID-19 infection. Methods: A retrospective review was conducted of the records of 96 patients with post-COVID pain syndrome. Those who were eligible for oral therapy or mesotherapy, included in the study. Patients receiving oral treatment with diclofenac potassium, thiocolchicoside and cyanocobalamin were included in one group (n = 46), and patients receiving intradermal mesotherapy with 2% lidocaine + cyanocobalamin were included in another group (n = 50). The results of the Visual Analogue Scale (VAS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) were individually assessed before and one week after the treatment. Findings: The participants were 40.2 ± 11.1 years old on average. Of the participants, 35.4% (n = 34) were male and 64.6% (n = 62) were female. Before treatment, there was no statistically significant difference between the patients in terms of VAS and LANSS scores. Following the treatment, a notable positive response was observed in both groups. Nevertheless, when compared to the oral treatment group, the mesotherapy group exhibited a more pronounced enhancement in VAS and LANSS scores (P < 0.001, P < 0.001, respectively). Implications: While both mesotherapy and oral therapy offer benefits in reducing pain and alleviating neuropathic symptoms in post-COVID pain syndrome, mesotherapy stands out as an especially effective and well-tolerated treatment method, surpassing the efficacy of the oral alternative.
dc.identifier.citationTopal, İ. ve Yılmaz, O. (2024). Effectiveness of mesotherapy in post-covid pain syndrome: retrospective cohort study of 96 patients. Clinical Therapeutics, 46(8), e1-e5. http://dx.doi.org/10.1016/j.clinthera.2024.05.004
dc.identifier.doi10.1016/j.clinthera.2024.05.004
dc.identifier.endpagee5
dc.identifier.issn0149-2918
dc.identifier.issn1879-114X
dc.identifier.issue8
dc.identifier.pmid38910071
dc.identifier.scopus2-s2.0-85196631362
dc.identifier.scopusqualityQ1
dc.identifier.startpagee1
dc.identifier.urihttp://dx.doi.org/10.1016/j.clinthera.2024.05.004
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12913
dc.identifier.volume46
dc.identifier.wosWOS:001306617100001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTopal, İlknur
dc.institutionauthorid0000-0002-5904-2980
dc.language.isoen
dc.relation.ispartofClinical Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID 19
dc.subjectMesotherapy
dc.subjectNeuropathic Pain
dc.titleEffectiveness of mesotherapy in post-covid pain syndrome: retrospective cohort study of 96 patients
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Topal-İlknur-2024.pdf
Boyut:
632.06 KB
Biçim:
Adobe Portable Document Format
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: